Compare BioNano Genomics Inc (BNGO) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs HSBC Holdings plc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while HSBC Holdings plc trades at $100.02 (market cap $337.30B). The key difference: HSBC Holdings plc is far larger — about 25553× BioNano Genomics Inc's market cap, and HSBC Holdings plc pays a 3.78% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HSBC | |
|---|---|---|
Market Cap | $13.20M | $337.30B |
Sector | Health | Technology |
52-Week High | $4.92 | $99.25 |
52-Week Low | $1.09 | $61.30 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
HSBC trades at $98.09, down 1.01% today but near its 52-week high of $99.47. Technical indicators show a bullish trend with strong moving average support. The bank reported $71.02B revenue and $22.29B net income for 2025, maintaining a robust 30.81% net margin. Recent news highlights strategic moves including AI partnerships with Google Cloud and potential divestitures of non-core units like its Turkey business.
HSBC presents a balanced investment case with steady profitability and strategic refocusing, but faces risks from global economic sensitivity and regulatory challenges. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
